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therapy is a clinically safe, noninvasive, nonsystemic treatment for
major depressive disorder. Objective: We evaluated the cost-
effectiveness of rTMS versus pharmacotherapy for the treatment of
patients with major depressive disorder who have failed at least two
adequate courses of antidepressant medications. Methods: A 3-year
Markov microsimulation model with 2-monthly cycles was used to
compare the costs and quality-adjusted life-years (QALYs) of rTMS
and a mix of antidepressant medications (including selective
serotonin reuptake inhibitors, serotonin and norepinephrine reup-
take inhibitors, tricyclics, noradrenergic and speciﬁc serotonergic
antidepressants, and monoamine oxidase inhibitors). The model
synthesized data sourced from published literature, national cost
reports, and expert opinions. Incremental cost-utility ratios were
calculated, and uncertainty of the results was assessed using
univariate and multivariate probabilistic sensitivity analyses.
Results: Compared with pharmacotherapy, rTMS is a dominant/
cost-effective alternative for patients with treatment-resistantee front matter Copyright & 2015, International S
r Inc.
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ty Drive, Meadowbrook, Logan, QLD 4131, Australdepressive disorder. The model predicted that QALYs gained with
rTMS were higher than those gained with antidepressant medica-
tions (1.25 vs. 1.18 QALYs) while costs were slightly less (AU $31,003
vs. AU $31,190). In the Australian context, at the willingness-to-pay
threshold of AU $50,000 per QALY gain, the probability that rTMS
was cost-effective was 73%. Sensitivity analyses conﬁrmed the
superiority of rTMS in terms of value for money compared with
antidepressant medications. Conclusions: Although both pharma-
cotherapy and rTMS are clinically effective treatments for major
depressive disorder, rTMS is shown to outperform antidepressants
in terms of cost-effectiveness for patients who have failed at least
two adequate courses of antidepressant medications.
Keywords: antidepressant, cost effectiveness analysis, economic
evaluation, Markov model, microsimulation, repetitive transcranial
magnetic stimulation.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Major depressive disorder (MDD) is a signiﬁcant burden to many
health care systems. It is a chronic and debilitating disease, and it
signiﬁcantly decreases quality of life [1,2]. It is one of the most
common of all psychiatric disorders and ranks among the leading
causes of disability worldwide [3]. Although many patients with
depression respond to ﬁrst-line medication and psychotherapy
treatments, an estimated 20% to 40% of the patients are unable to
tolerate pharmacotherapy or do not beneﬁt from these treat-
ments after repeated attempts [3]. In addition, even with suc-
cessful acute treatment outcomes, the long-term durability of
response among treatment-resistant patients is poor. A recent
review reported that the rate of recurrence of MDD, treated in
specialized mental health settings, was very high: 60% after
5 years, 67% after 10 years, and 85% after 15 years [1]. Patients
with treatment-resistant depression (TRD) contribute to a dis-
proportionately high burden of illness than do patients whorespond to treatment; they are twice as likely to be hospitalized
and have higher treatment costs [2].
Repetitive transcranial magnetic stimulation (rTMS) therapy is
a noninvasive, nonsystemic therapeutic device offering treat-
ment that uses pulsed magnetic ﬁelds at magnetic resonance
imaging strength to induce an electric current in a localized
region of the cerebral cortex. During the rTMS session, the patient
is conscious and there is no requirement for an anesthetic or
muscle relaxants. A treatment session usually lasts approxi-
mately 40 minutes and is normally performed three to ﬁve times
a week over a period of 4 to 6 weeks. After each session, patients
may continue with their daily work or other routines. rTMS
produces a clinical beneﬁt without the systemic adverse effects
typical of oral medications and appears to have no adverse
effects on cognition [4–7]. rTMS involves an electromagnetic coil
and is not suitable in patients with metal items such as cochlear
implants and implanted electrodes. It is also not recommended
for patients who are at risk of epileptic seizures, who areociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Health Economics, Menzies Health Institute Queensland, Grifﬁth
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dependence [5].
Clinical practice guidelines stipulate that current options for
TRD are antidepressant medications, rTMS, and electroconvul-
sive therapy (ECT). In dozens of small trials, however, rTMS has
been compared only with ECT mostly because they are both
classiﬁed as physical therapies. ECT, however, is commonly used
in emergency settings for psychotic patients, whereas rTMS is
indicated for a wider range of mild to severe MDD. In addition,
many patients with MDD are unable to tolerate the adverse
effects of ECT or refuse to have ECT because of the associated
stigma or fear about potential adverse effects (e.g., cognitive
impairment). As such, it has been suggested that ECT is comple-
mentary, rather than a replaceable treatment, to rTMS and
standard pharmacotherapies [8].
Simpson et al. [9] is the only study that compared pharmaco-
therapies and rTMS in the treatment of MDD. It concluded that
rTMS provided a net cost saving compared with antidepressant
medications [9]. Two studies compared rTMS with ECT and
arrived at different conclusions [10,11]. Kozel et al. [11] (US-based)
suggested that rTMS would be a cost-effective treatment for
patients with MDD compared with ECT alone over 12 months,
whereas Knapp et al. [10] (UK-based) found that rTMS has a very
low probability of being a cost-effective alternative to ECT over 6
months.
Because of the paucity of health economic assessments of
rTMS for health service decision making, the purpose of this study
was to investigate the cost-effectiveness of rTMS compared with
pharmacotherapies for patients with TRD within the context of the
Australian health system. We sought to use updated evidence to
populate our economic model and ascertain whether our results
corroborated the short-term ﬁndings from Simpson et al. [9].Methods
Overview
A hypothetical health state transition (Markov) model was used
to combine data on the health care costs and health effects of
rTMS and antidepressants over 3 years. The study population
was patients with MDD who have failed two adequate medication
trials from two different classes of drugs. Using a health system
perspective, the key outcome was the incremental cost per
quality-adjusted life-year (QALY), which represents the addi-
tional cost of rTMS per additional QALY compared with anti-
depressants. The stability of the results was thoroughly tested in
sensitivity analyses.
Treatment Strategies
Two main treatment strategies were considered: rTMS and
pharmacotherapies (standard antidepressant medications). The
model considers a mix of pharmacotherapies because in practice,
a large variety of antidepressants are prescribed for patients with
MDD depending on previous treatments, medication tolerance,
and resistance. The antidepressant mix includes selective sero-
tonin reuptake inhibitors, which account for a large share of MDD
medications in Australia, followed by serotonin and norepinephr-
ine reuptake inhibitors, tricyclics, noradrenergic and speciﬁc
serotonergic antidepressants, reversible inhibitor of monoamine
oxidase A, and monoamine oxidase inhibitors [12].
The model assumed that other standard psychotherapies (i.e.,
talking therapies) were maintained during both treatment
options. ECT, augmentation (e.g., lithium and atypical antipsy-
chotic medications), and hospitalizations were available for those
who failed the two main treatments.Model Structure
A Markov microsimulation model was constructed and analyzed
in TreeAge Pro 2014 software. The model duration was 3 years
with 2-monthly cycles. Eight health states were used to account
for acute or continuing treatments, combinations of responsive-
ness to treatment and relapse options, and deaths (see File 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.04.004). The MDD health states were based on the 17-item
Hamilton Depression Rating Scale (HAM-D17), which is one of the
most widely used and accepted measures for rating the severity
of depression symptoms. In the absence of long-term clinical
data, the duration of 3 years was chosen to track several courses
of treatment per patient, which is typical of clinical practice.
Patients entered the model and moved between the various
health states according to their treatments, their response to
therapies, and their chance of remission or relapse. The proba-
bility of gaining remission or regressing varied according to the
strategy under analysis (either rTMS or antidepressant). After this
point, the model for both strategies was identical in incorporating
the probabilities of receiving salvage treatments and their efﬁ-
cacy outcomes (ECT, augmentation, and hospitalization) and the
probability of having adverse events during treatment.
Data Inputs and Sources
To identify relevant evidence to populate the model, the
Cochrane Library and Medline databases were searched. In both
instances, a basic search strategy was used with key words (and
their combinations) such as major depressive disorder, major
depression, rTMS, antidepressant, ECT, treatment resistant. A
manual search of the references of each identiﬁed article of
interest was also completed for further information. Other
sources of information included national epidemiological reports
and hospital cost reports (Table 1).
Probabilities
The treatment effects (probabilities of gaining response or remis-
sion) for rTMS are extensively reported in the literature. The
range is wide, however, due to trial design and sample size
variations. Meta-analyses also report varying response and
remission rates, depending on the comparators, treatment fre-
quency (low vs. high), and frontal side (left, right, or bifrontal) [13–
16]. To calculate the pooled estimate of the treatment effect for
all relevant studies, meta-analyses were performed using the
random-effect inverse variance–weighted method for binary out-
comes (see File 1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2015.04.004). The response and remission
rates for rTMS were estimated as 37.5% and 21.5%, respectively.
The efﬁcacy outcome for antidepressant medication was derived
from the STAR*D trial [17,18]. This study reported major out-
comes (remission, response, and adverse effects) for different
patient groups including patients who failed two adequate anti-
depressant courses in their current illness episode. The reported
response and remission rates for antidepressant medications
were 16.8% and 13.6%, respectively.
The probabilities of regressing after a period of remission for
both rTMS and antidepressant medications are not reported in
the literature. Studies, however, have reported information on
worsening and relapse rates for rTMS [6,19], antidepressants [17],
and ECT treatment [20]. These rates were converted to proba-
bilities of losing remission (regressing). Treatment efﬁcacy tends
to decrease if patients develop resistance [9,18,21]; however, the
decrement rate is not reported quantitatively in the literature.
The rates of efﬁcacy decrement (for each subsequent treatment)
were therefore assumed to be 20% and 15% of remission and
response rates, respectively. It was also assumed that 75% of the
Table 1 – Summary of variables used in the economic model.
Description Base
case
Distribution Low High Sources and assumptions
Transition probabilities
rTMS
Remission: First treatment 21.5% Beta 19.7% 31.2% Meta-analysis (File 1 in
Supplemental Materials)
Response: First treatment 37.5% Beta 33.2% 48.7% Meta-analysis (File 1 in
Supplemental Materials)
Start maintenance 10.0% Beta 5.0% 15.0% Expert opinion*
Lose remission (no maintenance) 16.6% Beta 10.0% 20.0% [6,17–20]
Lose remission with maintenance 12.0% Beta 8.0% 16.0% [6,17–20]
Antidepressant medications
Remission: First treatment 13.6% Beta 13.0% 36.8% [17,18]
Response: First treatment 16.8% Beta 16.0% 48.6% [17,18]
Lose remission 28.1% Beta 20.0% 40.0% [17,18]
ECT (after failing rTMS or antidepressants)
Remission: First treatment 46.3% Beta 20.0% 70.0% Meta-analysis (File 1 in
Supplemental Materials)
Response: First treatment 60.9% Beta 40.0% 80.0% Meta-analysis (File 1 in
Supplemental Materials)
Lose remission 22.3% Beta 15.0% 35.0% [20]
For all treatment arms
Hospitalization 10.4% Beta 8.0% 12.0% Calculated from literature
Gaining REM after hospitalization 35.0% Beta 20.0% 50.0% Assumption
REM: % decrement for each subsequent
treatment
20.0% Triangular 15.0% 25.0% Assumption
RESP: % decrement for each subsequent
treatment
15.0% Triangular 10.0% 20.0% Assumption
Retreatment after relapse 36.2% Beta 25.0% 45.0% Expert opinion*
Relapse from partial remission 50.0% Beta 40.0% 71.0% [17]
Relapse: % increase for each subsequent
treatment
10.0% Triangular 8.0% 12.0% [17]
Getting ECT after failing the main treatment 25.0% Beta 20.0% 30.0% Assumption
Having adverse events during treatment 5.80% Beta 4.0% 8.0% [17]
Health utilities
Remission (HAM-D17 score o8) 0.860 Beta 0.750 0.900 [22,23]
Partial remission (mild-moderate 8 r HAM-D17
score o20)
0.710 Beta 0.650 0.820 [22,23]
No response (severe-very severe HAM-D17 score
Z20)
0.520 Beta 0.250 0.580 [22,23]
Disutility for antidepressant treatment 0.066 Triangular 0.040 0.100 [22,23]
Disutility for rTMS treatment 0.101 Triangular 0.050 0.150 Estimation
Disutility for ECT treatment 0.104 Triangular 0.500 0.150 Estimation
Hospitalization (severe-very severe with
suicidal risk HAM-D17 score Z20)
0.300 Beta 0.090 0.400 [22,23]
Resources and cost components (2013–2014 AUD)
rTMS
Number of acute sessions 28.3 Triangular 20.0 30.0 [4]; Expert opinion*
Number of maintenance sessions 4.0 Triangular 3.0 5.0 Expert opinion*
Cost per session $150.00 Gamma $120.00 $180.00 Assumption  20%
Antidepressant
Months per course of treatment 3.0 Triangular 2.0 6.0 Expert opinion*
Cost per month $17.27 Gamma $13.82 $20.72 Calculation  20%
ECT
Number of sessions 10.0 Triangular 6.0 12.0 ECT literature
Cost per session $814.00 Gamma $651.20 $976.80 AR-DRG v.6  20%
Augmentation
Cost per course treatment $235.19 Gamma 204.1 359.0 Expert opinion* and calculation
Hospitalization
Average cost per hospitalization $14,021 Gamma $13,106 $20,484 AR-DRG v.6
Adverse events
Antidepressant $80.95 Gamma $64.76 $97.14 Calculation  20%
continued on next page
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Table 1 – continued
Description Base
case
Distribution Low High Sources and assumptions
rTMS $81.79 Gamma $65.43 $98.15 Calculation  20%
ECT $72.53 Gamma $58.03 $87.04 Calculation  20%
AR-DRG, Australian reﬁned diagnosis-related groups; AUD, Australian dollar; ECT, electroconvulsive therapy; HAM-D, Hamilton Depression
Rating Scale; REM, remission; RESP, response; rTMS, repetitive transcranial magnetic stimulation.
* The expert was a university professor in psychiatry and a practicing physician, and had no conﬂicts of interest to declare.
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start augmentation medication. In Australia, lithium is indicated
(and approved by the Pharmaceutical Beneﬁt Schedule) to aug-
ment antidepressants for patients with MDD. Off-label use,
however, includes atypical antipsychotic drugs such as aripipra-
zole, quetiapine, and olanzapine. The model used lithium aug-
mentation as the base case, and tested a mix of augmentation
therapies in the sensitivity analysis. Last, mortality risk was
assumed to be higher for patients in acute depression or in
mild/moderate depression than in the general population.
Resources and Costs
Costs related to all health care resource items for the economic
model are summarized in Table 1. All costs were converted to
monthly values to accommodate the 2-monthly cycle calculation.
For simplicity, cost per treatment course (for both rTMS and
antidepressant) was assumed to occur within one cycle. Psychi-
atric consultation for treatment and a management plan incurred
a cost for each treatment course. Subsequent psychiatric con-
sultations and short visits were part of regular MDD monitoring.
Each rTMS session was estimated to cost approximately AU
$150 covering the professional component and practice compo-
nents. Each acute rTMS course consists of an average number of
28 sessions [4] and lasts for a period of 4 to 6 weeks. Patients who
respond positively to treatment (i.e., observed reduction in HAM-
D17 score) will proceed to rTMS maintenance until potential
relapse or dropout. For rTMS maintenance, the average number
of sessions was estimated to be 26 per annum, equivalent to an
average of two rTMS sessions per month.
Each antidepressant (acute) treatment course was recom-
mended for at least 3 months. The monthly cost was calculated
as the weighted average of most commonly used antidepressant
drugs prescribed by Australian doctors (Table 1) [12]. This
resulted in a monthly cost of AU $17.30, equivalent to AU $52
per 3-monthly (acute) treatment course. If a patient’s condition
improved to full remission, further medication was not required
unless the patient had a relapse later.
For each treatment option, patients who failed two consec-
utive courses would move to either augmentation or ECT.
Augmentation agents included lithium and atypical antipsy-
chotic agents (e.g., quetiapine, aripiprazole, and olanzapine).
The total cost for augmentation included at least 2-month supply
of the medication, regular monitoring tests, and one psychiatrist
consultation in addition to standard antidepressant medications.
The ECT treatment cost covered 10 sessions with one psychiatric
visit. The costs for hospitalizations and individual adverse events
were identiﬁed by Sullivan et al. [22] and valued using Australian
national cost schedules (Table 1).
Health State Utility Values
To calculate QALYs, patient utility values were assigned to each
health state in the model. Fourteen published studies were
identiﬁed from a systematic review of clinical trials andeconomic evaluations of MDD treatment (limited to publications
after January 2000). Hawthorne et al.’s [23] estimates were used
for the model base case because they reported the utility weights
for Australians but still aligned with values reported in the wider
literature. There is limited information on the disutility from
adverse events associated with each treatment. The most rele-
vant study for this topic is Sullivan et al. [22] on the cost-
effectiveness of serotonin reuptake inhibitors and associated
adverse drug reactions in the United States. For the economic
model, the weighted averages of the disutilities of adverse events
relevant to each treatment were calculated, with the utility
values taken directly from Sullivan et al. [22].
Analyses
The main outcomes of the model were costs and quality-adjusted
life-years (QALYs), both discounted at 5% to reﬂect time prefer-
ences. For the base case, microsimulations were performed with
50,000 trials to achieve stable results. Mean costs and QALYs for
each treatment arm were produced to calculate the incremental
cost-effectiveness ratio (ICER). Univariate and multivariate proba-
bilistic sensitivity analyses were undertaken for key variables. The
95% conﬁdence intervals or the high and low values, where
available, were used to reﬂect wide variation in the base values.
Beta distributions were assigned for utilities and probabilities,
whereas gamma distributions were assigned for costs. All sensi-
tivity analyses were performed with 50,000 trials for result stability
and consistency with the base case. An upper threshold of AU
$50,000 per QALY was used to indicate cost-effective results.Results
Estimates of cost, effect, and ICER for the base case (3-year
horizon) are presented in Table 2 and on the cost-effectiveness
plane in Figure 1. The model predicted that QALYs gained with
rTMS were higher than QALYs gained with pharmacotherapy
(1.25 vs. 1.18 QALYs) while costs were slightly less (AU $31,003 vs.
AU $31,190). Therefore, in the base case, the rTMS option was
considered the superior alternative compared with pharmaco-
therapy for the treatment of treatment-resistant patients with
MDD. At a threshold of AU $50,000 per QALY gain, the probability
that rTMS was dominant was 32% and the probability that rTMS
was cost-effective compared with antidepressants was 41%.
Table 3 presents the effect of parameter changes on the ICER.
The analytical model was very robust with respect to all param-
eters. Univariate sensitivity analyses identiﬁed the most inﬂuen-
tial variables in the model: the probabilities of gaining and losing
remission after antidepressant treatment; the probability of
losing remission without rTMS maintenance; the probability of
losing remission after treatment; and the doses and costs
per session of rTMS and ECT. The model was not sensitive to
the utility values, and for most probability and cost variables
rTMS was a dominant alternative to antidepressant medication.
The multivariate analyses showed that the model results were
Fig. 1 – Microsimulation results in the Base case (3 year
horizon with 50,000 trials.) QALYs, quality-adjusted life-years.
Table 2 – Costs, effects, cost-effectiveness ratios, and net monetary beneﬁt (2013–2014 AUD).
Mean values 3 y (base case) 5 y (sensitivity analysis)
Antidepressant rTMS Antidepressant rTMS
Total cost $31,190 $31,003 $41,009 $39,693
Incremental total cost – –$187 – –$1,316
Total QALYs 1.18 1.25 1.53 1.63
Incremental total QALYS – 0.07 – 0.10
Cost/QALY $26,432 $24,803 $26,803 $24,352
Incremental cost per QALY – Dominant – Dominant
AUD, Australian dollar; QALY, quality-adjusted life-year; rTMS, repetitive transcranial magnetic stimulation.
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being dominant or cost-effective compared with antidepressants
exceeding 70%.
Additional sensitivity analyses were also performed on the
discount rates and model duration. When a longer time horizon
was applied (5 instead of 3 years), the average cost saving
increased to $1316 and the average QALY gain per patient was
0.10. This implies increasing cost-effectiveness in the medium
term for rTMS treatment versus standard pharmacotherapies. The
use of different discount rates had little impact on this overall
conclusion. At a 3% discount rate, rTMS was a superior strategy,
less costly, and more effective, compared with the antidepressant
medication. At a 7% discount rate, the ICER was AU $127 per QALY
gained, well below a willingness-to-pay threshold of AU $50,000.Discussion
A cost-effective treatment for treatment-resistant patients with
depression is an important challenge today because MDD is a
chronic and debilitating disease that signiﬁcantly decreases one’s
quality of life, and is a leading cause of disability worldwide [2,3].
rTMS has been received as a clinically effective and safe option for
treatment-resistant patients with MDD [4–7,24]. In this economic
evaluation, we have shown that rTMS is a cost-effective alter-
native to pharmacotherapy over 3 years. In general, patients with
treatment-resistant MDD gain slightly more quality of life at a
lower cost when treated with rTMS than with pharmacotherapies.
The results of the analyses suggest that there is a low probabilityof antidepressant medications being cost-effective compared with
rTMS at a willingness-to-pay level of AU $50,000 per QALY gain.
To date, rTMS therapy appears to have a high degree of safety
and acceptability among patients and clinicians [25]. The mag-
netic pulse produces an audible high-frequency clicking sound,
and ear protection (earplugs) is used during rTMS treatments.
Common adverse events observed with rTMS are mild to mod-
erate posttreatment headache and mild pain or discomfort at the
treatment area. The most signiﬁcant medical risk associated with
the use of rTMS therapy is the inadvertent induction of a seizure.
No seizures, however, were reported in the clinical research trials
of the NeuroStar rTMS Therapy System [25,26]. In postmarket
use, the prevalence of seizure with the NeuroStar rTMS Therapy
System, under recommended operating conditions, is estimated
to be less than 0.1% per patient and lower than what is typically
seen with routine antidepressant medications. There has also
been no evidence of emergent suicidal ideation during acute
treatment with the NeuroStar rTMS Therapy System.
In the time of ﬁscal challenge and rising burden of mental
illness, this cost-effectiveness evidence is timely and useful for
both policymakers and service providers in resource allocation.
Incorporating rTMS into the standard treatment algorithm for
MDD expands the choice set available for patients, especially for
those who develop intolerance to and/or fail pharmacotherapies.
rTMS can also replace ECT in a subgroup of patients without
psychotic symptoms or acute risks who are traditionally referred
for ECT. As a substitution therapy, rTMS will be a cost-saving
device for government budgets if more treatment-resistant
patients with MDD switch from antidepressant medication and/
or ECT to rTMS. That is, subsidizing rTMS is potentially an
efﬁciency-improvement strategy for the health system.
The ﬁndings from our model are consistent with conclusions
from the Simpson et al. [9] study despite signiﬁcant differences in
modeling approaches. Simpson et al. used a Markov cohort model
to compare rTMS with sham and pharmacotherapies under open-
label conditions and for patients who were exposed to at least
one but no more than four antidepressant medications. Based on
the data derived from the published STAR*D study [17] and on a
multicentre randomized controlled trial [21], the study found that
rTMS provided a net cost saving of US $1123 per QALY gained
compared with the current antidepressant medication therapies
[9]. Although our model relies on the same STAR*D study for the
clinical efﬁcacy of pharmacotherapies (in patients with TRD), the
efﬁcacy for rTMS was derived from a large meta-analysis rather
than one single study. This might better reﬂect the effectiveness
of rTMS in practice. In addition, Simpson et al.’s model did not
take into account the subsequent and rescue treatments (i.e.,
ECT, augmentation, and hospitalization) when patients failed
either rTMS or standard pharmacotherapies. Our model closely
mimics this pathway and thus better reﬂects the treatment
algorithm for MDD in “real” practice.
Table 3 – Summary of sensitivity analysis results (2013–2014 AUD).
Variables Antidepressants rTMS Cost-effectiveness results of
rTMS vs. antidepressants
Cost ($) QALY Cost ($) QALY
Utilities
Univariate 28,921–28,947 1.19–1.23 28,434–28,466 1.23–1.30 Dominant ¼ 100%
Multivariate (all utility values) 28,911 1.16 28,431 1.24 Dominant ¼ 97%; ICER o 50,000 ¼ 3%
Transition probabilities
Gaining remission after treated with
antidepressant
29,145 1.19 28,518 1.27 ICER 4 50,000 ¼ 10%; Dominated ¼ 1%
Losing remission without rTMS maintenance 28,923 1.19 28,483 1.27 ICER 4 50,000 ¼ 7%
Losing remission after treated with
antidepressant
28,577 1.20 28,441 1.27 ICER 4 50,000 ¼ 13%; Dominated ¼ 7%
Other transition probabilities (univariate) 28,833–29,400 1.19 28,388–28,951 1.26–1.27 Dominant ¼ 60%–100%; ICER o 50,000 ¼ 0%–40%
Multivariate (all probabilities) 31,103 1.18 30,423 1.25 Dominant ¼ 57%; ICER o 50,000 ¼ 34%;
Dominated ¼ 9%
Costs
rTMS dose for acute treatment 28,917 1.19 28,418 1.27 Dominant ¼ 98%; ICER o 50,000 ¼ 2%
rTMS cost per session 28,937 1.19 28,491 1.27 Dominant ¼ 67%; ICER o 50,000 ¼ 33%
ECT dose 28,876 1.19 28,400 1.27 Dominant ¼ 97%; ICER o 50,000 ¼ 3%
ECT cost per session 28,945 1.19 28,457 1.27 Dominant ¼ 89%; ICER o 50,000 11%
Augmentation (including lithium, atypical
antipsychotic drugs)
28,976 1.19 28,489 1.27 Dominant 100%
Other cost variables 28,919–28,945 1.19 28,437–28,459 1.27 Dominant ¼ 100%
Multivariate (all cost variables) 28,915 1.19 28,452 1.27 Dominant ¼ 71%; ICER o 50,000 ¼ 29%
All variables (1,000 simulations with 50,000 trials
each)
30,528 1.20 30,071 1.27 Dominant ¼ 56%; ICER o 50,000 ¼ 15%; ICER 4
50,000 ¼ 17%; Dominated ¼ 12%
AUD, Australian dollar; ECT, electroconvulsive therapy; ICER, incremental cost-effectiveness ratio; rTMS, repetitive transcranial magnetic stimulation.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 9 7 – 6 0 4 603We did not consider psychotherapies in this model because of
a lack of clinical evidence of rTMS versus psychotherapy (both
efﬁcacy and safety). Psychotherapies for patients with TRD
currently do not show deﬁnitive beneﬁts to warrant their use as
a comparator for these difﬁcult-to-treat patients. In addition, no
clinical studies have directly compared the efﬁcacy of rTMS
treatment to any form of psychotherapy. There are also no
high-quality studies comparing psychotherapies to pharmaco-
therapy or rTMS or placebo that are relevant for this article, that
is, those who failed to respond to two previous medication
treatments. Although an assessment of effectiveness or safety
between psychotherapy and rTMS is not possible within the
scope of this research, this option cannot be ruled out as being
potentially beneﬁcial to some patients.
Despite using the best available evidence to use in the model,
a number of assumptions were necessary. First, we have made
various assumptions in the decrements of efﬁcacy for subsequent
courses of the same treatment. We also calculated the proba-
bilities of losing remission from relapse rates (for the respective
treatments) under an assumption that the rate of losing remis-
sion is constant over time. Second, utility weights were all
sourced from the literature on patients with depression and
may be different to the modeled population (i.e. treatment-
resistant patients). Third, some cost estimates relied on expert
advice, which might not fully represent those of all clinicians in
current practice. The sensitivity analyses, however, showed that
the effect of the above assumptions was small, and, if present,
there was approximately 10% chance that antidepressants were a
cost-effective treatment compared with rTMS. Finally, our anal-
yses took an Australian perspective with the use of Australian-
speciﬁc costs, utilities, and background mortality. Generalizabil-
ity to other countries may be in question, but we believe that the
relativities of the unit costs for the different treatments would
likely be similar across jurisdictions.Conclusions
The study shows that rTMS is a cost-effective treatment alternative
for patients with MDD who have failed at least two adequate
courses of antidepressant medications. This result supports pro-
viders in deciding to subsidize rTMS to increase the diversity of
treatment options. This ﬁnding also has wider implications in
relation of improving cost efﬁciency within the health system.Acknowledgments
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